Cases of stomach cancer to fall over next decade

NewsGuard 100/100 Score

New cases of stomach cancer are set to plummet a further 25 per cent in the West over the next decade, indicates research published ahead of print in the journal Gut.

Stomach cancer is the fourth most common cancer, and the second leading cause of cancer related death, in the world.

The findings are based on the long term monitoring of the three types of cell changes indicative of subsequent stomach cancer.

The authors tracked all new cases of atrophic gastritis, intestinal metaplasia, and dysplasia recorded in the Dutch national registry of diseased tissue samples.

The monitoring period covered the years 1991 to 2005 and included almost 98,000 patients who had a routine tissue sample (biopsy) taken.

Most of the cases were intestinal metaplasia, which was diagnosed in almost 66,000 patients during the monitoring period.

The figures showed that the rate of new cases fell steadily by between 2.4 and 2.9% a year in women and men, respectively.

Dysplasia, which was diagnosed in just over 8500 patients, and atrophic gastritis, which was diagnosed in just over 23,000, both fell by more than 8% a year.

The fall in new cases of intestinal metaplasia and atrophic gastritis was even sharper after 1996, the figures showed.

On the basis of these trends, the authors calculate that new cases of gastric cancer will fall by 'at least 24%' over the next decade in the West, without the need for treatment.

The authors say that the fall in the number of cases of gastric inflammation caused by Helicobacter pylori infection largely explains the figures.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New microfluidic device improves the separation of tumor cells and clusters from malignant effusions